Vigonvita Life Sciences

This early-stage study tests a new drug called VV119 in healthy adults and people with schizophrenia. The main goal is to check if the drug is safe and how the body processes it. About 40 participants will take multiple doses to find the right amount for future studies.

This Phase 2 trial tests LV232, a new capsule for major depressive disorder, in 400 adults aged 18-65. Participants are randomly assigned to receive one of two doses of LV232, the active comparator escitalopram, or a placebo for 8 weeks. The main goal is to find the best dose and…

This early-stage study is testing a single dose of an experimental drug called VV913 in 56 healthy Chinese men aged 18 to 45. The goal is to see if the drug is safe and how the body processes it. Participants are randomly assigned to receive either VV913 or a placebo, and no dire…

This early-stage trial is testing a single oral dose of VV261 tablets in 58 healthy Chinese adults to see if it is safe and how the body processes it. Participants are randomly assigned to receive either VV261 or a placebo. The study does not aim to treat any disease, but to gath…

This study looks at how taking a new drug (VV119) with or without a standard meal changes its levels in the blood. Sixteen healthy Chinese adults will receive a single dose of VV119 under both conditions. The goal is to understand food's effect on drug absorption and safety, not …